Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 4/20 | 0.46 |
| ▸ | CDK4 | P11802 | 16/20 | 0.45 |
| ▸ | CCND1 | P24385 | 16/20 | 0.45 |
| ▸ | CCND2 | P30279 | 14/20 | 0.45 |
| ▸ | CCND3 | P30281 | 14/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 7/20 | 0.43 |
| ▸ | CDK2 | P24941 | 7/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 5/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 4/20 | 0.43 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.43 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.42 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.42 |
| ▸ | CDK1 | P06493 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL190132 | 0.84 | CDK4 (0.62) | PIK3CACDK4CCND1CCND2CCND3 | |
| SCHEMBL4218283 | 0.83 | CDK4 (0.54) | PIK3CACDK4CCND1CCND2CCND3 | |
| SCHEMBL190547 | 0.83 | CDK4 (0.61) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL4220885 | 0.82 | CDK4 (0.53) | PIK3CACDK4CCND1CCND2CCND3 | |
| SCHEMBL4218445 | 0.78 | PIK3CA (0.51) | PIK3CACDK4CCND1CCND2CCND3 | |
| SCHEMBL4226220 | 0.77 | PIK3CA (0.49) | PIK3CACDK4CCND1CCND2CCND3 | |
| SCHEMBL11928210 | 0.75 | KDM4E (0.47) | PIK3CACDK4CCND1CCND2CCND3 | |
| SCHEMBL4222668 | 0.74 | PIK3CA (0.45) | PIK3CACDK4CCND1CCND2CCND3 | |
| SCHEMBL4225857 | 0.74 | PIK3CA (0.45) | PIK3CACDK4CCND1CCND2CCND3 | |
| SCHEMBL4232744 | 0.74 | PIK3CA (0.45) | PIK3CACDK4CCND1CCND2CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931670-B1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3K | EXELIXIS INC (US) | 2012-09-12 | — | — | EP | claimed |
| US-8247408-B2 | Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer | EXELIXIS, INC. (US) | 2012-08-21 | — | — | US | claimed |
| US-20090062274-A1 | Pyridopyrimidinone inhibitors of pi3kalpha | EXELIXIS, INC (US) | 2009-03-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062274-A1 | Pyridopyrimidinone inhibitors of pi3kalpha | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885CDK4 265/4885CCND1 805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.